Neovasc

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neovasc Inc. is a specialty medical device company that develops and manufactures products for the rapidly growing cardiovascular device marketplace.Neovasc Inc. offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners.

Vancouver, British Columbia--(Newsfile Corp. - August 10, 2020) -  Neovasc Inc.

Neovasc Announces US$12.6 Million Registered Direct Offering Priced At-the-Market

Neovasc, Inc. (NVCN) CEO Fred Colen on Q2 2020 Results - Earnings Call Transcript

Neovasc (NVCN) delivered earnings and revenue surprises of -35.59% and -5.33%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Neovasc (NVCN) Reports Q2 Loss, Lags Revenue Estimates

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 6, 2020) -  Neovasc, Inc.

Neovasc Announces Second Quarter Financial Results

Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Neovasc (NVCN) Report Negative Q2 Earnings? What You Should Know

Vancouver, British Columbia and Minneapolis, Minnesota and Frankfurt, Germany--(Newsfile Corp. - July 24, 2020) - Neovasc, Inc.

Neovasc Reducer(TM) Featured In Germany's Second Largest National Newspaper

VANCOUVER, Canada, MINNEAPOLIS, MN and FRANKFURT, Germany , July  24, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that the Neovasc Reducer™ (the “Reducer”) was featured in a supplement titled: “Volkskrankheiten” or “Common Diseases” in Frankfurter Allgemeine Zeitung(FAZ), the second largest national newspaper by circulation in Germany. The supplement will be mailed to subscribers, reaching an estimated audience of almost 500,000 and should be available in the waiting areas of physician offices across Germany over the coming months.  

Neovasc Reducer™ Featured In Germany’s Second Largest National Newspaper

VANCOUVER and MINNEAPOLIS, July  09, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the Circulatory System Devices Panel of the Medical Devices Advisory Committee will review the premarket approval application (PMA) for the Neovasc Reducer™ device (“Reducer”) at its October 27, 2020 meeting. Neovasc is seeking approval for Reducer in the U.S. for the treatment of patients suffering from refractory angina pectoris despite guideline directed medical therapy, who are unsuitable for revascularization by coronary artery bypass grafting (CABG) or by percutaneous coronary intervention (PCI).

Neovasc Announces Circulatory System Devices Panel Meeting Date for Neovasc Reducer™ Device

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 9, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the Circulatory System Devices Panel of the Medical Devices Advisory Committee will review the premarket approval application (PMA) for the Neovasc Reducer™ device ("Reducer") at its October 27, 2020 meeting. Neovasc is seeking approval for Reducer in...

Neovasc Announces Circulatory System Devices Panel Meeting Date for Neovasc Reducer(TM) Device

Company to Report Full Financial Results on August 6, 2020Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 6, 2020) -  Neovasc, Inc. (NASDAQ: NVCN), (TSX: NVCN) today announced preliminary revenue results for the second quarter of 2020. Revenue for the quarter ended June 30, 2020 was approximately $295,000. Revenues were negatively impacted by a reduction in Reducer procedures that began in mid-March and persisted through early June. Despite a marked slowdown in the number of implants and related revenue from the Reducer...

Neovasc Provides Update on Second Quarter Results

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 29, 2020) - Neovasc, Inc. (NASDAQ: NVCN), (TSX: NVCN) ("Neovasc" or the "Company"), today announced that the Neovasc Reducer™ ("Reducer") and Tiara™ ("Tiara") program were recently featured at two industry conferences.The Tiara Mitral Valve Replacement program was featured at both the PCR e-Course and the TVT Connect conference.During the courses, Lenard Conradi M.D., University Heart Center Hamburg, Germany, and Gorav Ailawadi, M.D., M.B.A., University of Virginia,...

Neovasc Reducer(TM) and Tiara(TM) Featured at Leading Industry Virtual Conferences

VANCOUVER and MINNEAPOLIS, MN, June  29, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  Neovasc, Inc.  ("Neovasc" or the "Company") ( NASDAQ ,  TSX : NVCN), today announced that the Neovasc Reducer™ (“Reducer”) and Tiara™ (“Tiara”) program were recently featured at two industry conferences.

Neovasc Reducer™ and Tiara™ Featured at Leading Industry Virtual Conferences

VANCOUVER and MINNEAPOLIS, June  26, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today announced positive interim results of the REDUCER-I study during the PCR E-Course. Stefan Verheye, MD, PhD, ZNA Middelheim, Antwerp, Belgium presented the results of the trial during the Hotline and Innovation Session.

Neovasc  Announces Positive Interim Results from REDUCER-I Study

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 26, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced positive interim results of the REDUCER-I study during the PCR E-Course. Stefan Verheye, MD, PhD, ZNA Middelheim, Antwerp, Belgium presented the results of the trial during the Hotline and Innovation Session.REDUCER-I is a multi-center, international, three-arm prospective and retrospective observational study enrolling up to 400 patients suffering from refractory angina. The...

Neovasc Announces Positive Interim Results from REDUCER-I Study

VANCOUVER and MINNEAPOLIS, June  25, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), announced that it received written notification yesterday (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum market value requirement set forth in the rules for continued listing on the Nasdaq Capital Market (the “Listing Rules”).

Neovasc Regains Compliance  with Nasdaq Minimum Market Value Rule

VANCOUVER and MINNEAPOLIS, MN, June  16, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that it has closed its previously announced registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules of an aggregate of 3,883,036 units (the "Units") at a price of US$ 2.97375 per Unit for aggregate gross proceeds to the Company of approximately US$11.5 million, before deducting placement agent’s fees and estimated expenses of the Offering payable by the Company.

Neovasc Announces Closing of $11.5 Million Registered Direct Offering Priced At-The-Market

Vancouver, BC, June  12, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 3,883,036 common shares at a purchase price of US$2.97375 per common share in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules for aggregate gross proceeds to the Company of approximately US$11.5 million, before deducting placement agent’s fees and estimated expenses of the Offering payable by the Company.  The Offering is expected to close on or about June 16, 2020, subject to customary closing conditions.

Neovasc Announces $11.5 Million Registered Direct Offering Priced At-The-Market

VANCOUVER and MINNEAPOLIS, MN, June  09, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (“Reducer”) and Tiara™ (“Tiara”) program will be featured at two industry conferences this month. At the PCR e-Course, being held June 25-27, Tiara TA (transapical), Tiara TF (transfemoral/transseptal) systems and Reducer will be featured in three separate sessions:

Neovasc Reducer™ and Tiara™ Program to be Highlighted at Leading Industry Virtual Conferences

VANCOUVER and MINNEAPOLIS, MN, June  04, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  Neovasc Inc.  ("Neovasc" or the "Company") ( NASDAQ ,  TSX : NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that, further to its press release dated May 26, 2020, the Company has issued a final convertible note in the principal amount US$1 million to Strul Medical Group, LLC (“Strul”). Following the earlier issuance to Strul of a convertible note in the principal amount of US$4 million and 2,573,959 warrants (the “Warrants”), the Company has raised aggregate gross proceeds of US$5 million (the “Offering”). 

Neovasc Announces Closing of Final Convertible Debt Issuance for Gross Proceeds of US$5.0 Million

Elective Interventional Procedures Resume in Germany

Neovasc Reducer Spotlighted in Leading German Public Television Program

Less invasive approach provides hope for the millions of patients that suffer from leaky mitral valves

Neovasc Has Filed for CE Mark for Tiara TA Transapical Mitral Valve Replacement System

VANCOUVER and MINNEAPOLIS, May  26, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today 1) an offering (“Offering”) of convertible notes (“2020 Notes”) and warrants (“2020 Warrants”) to Strul Medical Group for gross proceeds of up to US$5.0 Million; 2) all of the Company’s remaining 2017 Notes have been fully repaid or converted (“2017 Note Settlement”); 3) Neovasc entered into a settlement agreement with certain holders (the “2017 Holders”) of the 2017 Notes whereby the Company will issue warrants (“Settlement Warrants”) to such holders and 4) Neovasc entered into an agreement (“Exchange Agreement”) to exchange most of the outstanding warrants issued in January 2020 for common shares of the Company (“Exchange Shares”).  The combined transactions improve the fully diluted share capital of the Company, and are designed to allow the Company to pursue refinancing options with long term investors who understand the overall potential of the Company’s portfolio of products.

Neovasc Announces Offering of Convertible Debt and Warrants for Gross Proceeds of up to US$5.0 Million, Warrant Exchange Transaction and Repayment of 2017 Convertible Notes and Related Settlement

Neovasc, Inc. (NVCN) CEO Fred Colen on Q1 2020 Results - Earnings Call Transcript

VANCOUVER and MINNEAPOLIS, May  01, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement and minimally invasive devices for the treatment of refractory angina, today announced that the Nasdaq Hearings Panel has granted the Company’s request for an extension through August 17, 2020 to evidence compliance with the $35 million minimum market value of listed securities (“MVLS”) requirement for continued listing on The Nasdaq Capital Market (“Nasdaq”).

Neovasc Announces Receipt of Nasdaq Extension to Satisfy Market Cap Rule

Neovasc (NVCN) expects an approval from the FDA for Reducer by end of 2020.

News for Neovasc Stock (NVCN)